2018, Number Esp
<< Back Next >>
Sal Jal 2018; 5 (Esp)
Vacunas contra el Virus del Dengue, Chikungunya, Zika y Mayaro
Palomares-Marín J, Rodríguez-Preciado SY, Hernández-Andrade L, Hernández-Cañaveral II
Language: Spanish
References: 42
Page: 109-115
PDF size: 312.91 Kb.
Text Extraction
No abstract.
REFERENCES
Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al. Dengue: a continuing global threat. Nat Rev Microbiol [Internet]. 2010 Dec 1;8:S7. Available from: http://dx.doi. org/10.1038/nrmicro2460
Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol [Internet]. 2013;158(7):1445–59. Available from: https://doi.org/10.1007/s00705-013-1645-3
Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature [Internet]. 2013 Apr 7;496:504. Available from: http:// dx.doi.org/10.1038/nature12060
Cedillo-Barrón L, García-Cordero J, Bustos-Arriaga J, León-Juárez M, Gutiérrez-Castañeda B. Antibody response to dengue virus. Microbes Infect [Internet]. 2014;16(9):711– 20. Available from: http://www.sciencedirect.com/science/ article/pii/S1286457914000987
de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WMPB, Kraus A, et al. In-Depth Analysis of the Antibody Response of Individuals Exposed to Primary Dengue Virus Infection. PLoS Negl Trop Dis [Internet]. 2011 Jun 21;5(6):e1188. Available from: https://doi.org/10.1371/journal.pntd.0001188
Capeding MR, Tran NH, Hadinegoro SRS, Ismail HIHJM, Chotpitayasunondh T, Chua MN, et al. Clinical effi cacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet [Internet]. 2018 Apr 16;384(9951):1358–65. Available from: http://dx.doi.org/10.1016/S0140-6736(14)61060-6
Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, et al. Effi cacy of a Tetravalent Dengue Vaccine in Children in Latin America. N Engl J Med [Internet]. 2014 Nov 3;372(2):113–23. Available from: https://doi.org/10.1056/ NEJMoa1411037
Vicente CR, Herbinger K-H, Fröschl G, Malta Romano C, de Souza Areias Cabidelle A, Cerutti Junior C. Serotype infl uences on dengue severity: a cross-sectional study on 485 confi rmed dengue cases in Vitória, Brazil. BMC Infect Dis [Internet]. 2016;16(1):320. Available from: https://doi.org/10.1186/s12879- 016-1668-y
Osorio JE, Partidos CD, Wallace D, Stinchcomb DT. Development of a recombinant, chimeric tetravalent dengue vaccine candidate. Vaccine [Internet]. 2015;33(50):7112–20. Available from: http:// www.sciencedirect.com/science/article/pii/S0264410X15016552
Whitehead SS. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine diff erent from the Sanofi -Pasteur CYDTM vaccine? Expert Rev Vaccines [Internet]. 2016 Apr 2;15(4):509–17. Available from: https://doi.org/10.1586/14760584.2016.1115727
L Innis B, H Eckels K. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Vol. 69, Th e American journal of tropical medicine and hygiene. 2004. 1-4 p.
Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL, et al. Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Naive Infants. Am J Trop Med Hyg. 2011;85(2).
Aggarwal A, Garg N. Newer vaccines against mosquito-borne diseases. Indian J Pediatr. 2017;1–7.
Kantor IN. Dengue, zika, chikungunya and the development of vaccines. Medicina (B Aires). 2018;78(1):23–8.
Ramsauer K, Tangy F. Chikungunya Virus Vaccines: Viral Vector–Based Approaches. J Infect Dis [Internet]. 2016 Dec 15;214(suppl_5):S500–5. Available from: http://dx.doi. org/10.1093/infdis/jiw369
Erasmus JH, Rossi SL, Weaver SC. Development of Vaccines for Chikungunya Fever. J Infect Dis [Internet]. 2016 Dec 15;214(suppl_5):S488–96. Available from: http://dx.doi. org/10.1093/infdis/jiw271
Silva JVJ, Lopes TRR, Oliveira-Filho EF de, Oliveira RAS, Durães- Carvalho R, Gil LHVG. Current status, challenges and perspectives in the development of vaccines against yellow fever, dengue, Zika and chikungunya viruses. Acta Trop [Internet]. 2018;182:257–63. Available from: http://www.sciencedirect.com/science/article/ pii/S0001706X17314444
Rezza G. Do we need a vaccine against chikungunya? Pathog Glob Health [Internet]. 2015 Jun 1;109(4):170–3. Available from: https://doi.org/10.1179/2047773215Y.0000000017
Ahola T, Couderc T, Ng LFP, Hallengärd D, Powers A, Lecuit M, et al. Th erapeutics and Vaccines Against Chikungunya Virus. Vector-Borne Zoonotic Dis [Internet]. 2015 Apr 1;15(4):250–7. Available from: https://doi.org/10.1089/vbz.2014.1681
Dick GWA, Kitchen SF, Haddow AJ. Zika Virus (I). Isolations and serological specifi city. Trans R Soc Trop Med Hyg [Internet]. 1952;46(5):509–20. Available from: http://www.sciencedirect. com/science/article/pii/0035920352900424
Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika Virus. N Engl J Med [Internet]. 2016 Mar 30;374(16):1552–63. Available from: https://doi.org/10.1056/NEJMra1602113
Darrigo LG, de Sant’Anna Carvalho AM, Machado CM. Chikungunya, Dengue, and Zika in Immunocompromised Hosts. Curr Infect Dis Rep [Internet]. 2018 Mar 17;20(4):5. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857271/
Durbin AP, Whitehead SS. Zika Vaccines: Role for Controlled Human Infection. J Infect Dis [Internet]. 2017 Dec 16;216(suppl_10):S971–5. Available from: http://dx.doi. org/10.1093/infdis/jix491
Casos Confi rmados de Infección por Virus Zika 2018 [Internet]. Secretaria de Salud, Dirección General de Epidemiología. 2018 [cited 2018 Mar 28]. Available from: https://www.gob.mx/ salud/documentos/casos-confi rmados-de-infeccion-por-viruszika- 2018
Blackman MA, Kim I-J, Lin J-S, Th omas SJ. Challenges of Vaccine Development for Zika Virus. Viral Immunol [Internet]. 2017 Dec 11;31(2):117–23. Available from: https://doi.org/10.1089/ vim.2017.0145
Singh RK, Dhama K, Karthik K, Tiwari R, Khandia R, Munjal A, et al. Advances in Diagnosis, Surveillance, and Monitoring of Zika Virus: An Update. Front Microbiol [Internet]. 2017 Jan 19;8:2677. Available from: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC5780406/
Poland GA, Kennedy RB, Ovsyannikova IG, Palacios R, Ho PL, Kalil J. Development of vaccines against Zika virus. Lancet Infect Dis [Internet]. 2018 Apr 16; Available from: http://dx.doi. org/10.1016/S1473-3099(18)30063-X
Lazear HM, Diamond MS. Zika Virus: New Clinical Syndromes and Its Emergence in the Western Hemisphere. Pierson TC, editor. J Virol [Internet]. 2016 May 15;90(10):4864–75. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859708/
Abbink P, Larocca RA, De La Barrera RA, Bricault CA, Moseley ET, Boyd M, et al. Protective effi cacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science (80- ) [Internet]. 2016 Sep 9;353(6304):1129 LP-1132. Available from: http://science.sciencemag.org/content/353/6304/1129.abstract
Larocca RA, Abbink P, Peron JPS, de A. Zanotto PM, Iampietro MJ, Badamchi-Zadeh A, et al. Vaccine protection against Zika virus from Brazil. Nature [Internet]. 2016 Jun 28;536:474. Available from: http://dx.doi.org/10.1038/nature18952
Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, et al. Zika virus protection by a single low-dose nucleosidemodifi ed mRNA vaccination. Nature [Internet]. 2017 Feb 2;543:248. Available from: http://dx.doi.org/10.1038/nature21428
Kim E, Erdos G, Huang S, Kenniston T, Falo Jr. LD, Gambotto A. Preventative Vaccines for Zika Virus Outbreak: Preliminary Evaluation. EBioMedicine [Internet]. 2018 Apr 16;13:315–20. Available from: http://dx.doi.org/10.1016/j.ebiom.2016.09.028
Figueiredo MLG de, Figueiredo LTM. Emerging alphaviruses in the Americas: Chikungunya and Mayaro. Vol. 47, Revista da Sociedade Brasileira de Medicina Tropical . scielo ; 2014. p. 677– 83.
Mackay IM, Arden KE. Mayaro virus: a forest virus primed for a trip to the city? Microbes Infect [Internet]. 2016;18(12):724–34. Available from: http://www.sciencedirect.com/science/article/ pii/S1286457916301666
Hotez PJ, Murray KO. Dengue, West Nile virus, chikungunya, Zika—and now Mayaro? PLoS Negl Trop Dis [Internet]. 2017 Aug 31;11(8):e0005462. Available from: https://doi.org/10.1371/ journal.pntd.0005462
García-Rejón J. Del virus Mayaro y su probable entrada a México y su impacto en la Península Yucatán. Cienc Y HUMANISMO EN LA SALUD. 2017;3(3):1–3.
Weise WJ, Hermance ME, Forrester N, Adams AP, Langsjoen R, Gorchakov R, et al. A Novel Live-Attenuated Vaccine Candidate for Mayaro Fever. PLoS Negl Trop Dis [Internet]. 2014 Aug 7;8(8):e2969. Available from: https://doi.org/10.1371/journal. pntd.0002969
Carvalho CAM, Sousa IP, Silva JL, Oliveira AC, Gonçalves RB, Gomes AMO. Inhibition of Mayaro virus infection by bovine lactoferrin. Virology [Internet]. 2014;452–453:297–302. Available from: http://www.sciencedirect.com/science/article/pii/ S004268221400035X
Esposito DLA, Fonseca BAL da. Will Mayaro virus be responsible for the next outbreak of an arthropod-borne virus in Brazil? Brazilian J Infect Dis [Internet]. 2017;21(5):540–4. Available from: http://www.sciencedirect.com/science/article/pii/ S1413867017301630
Mavian C, Rife BD, Dollar JJ, Cella E, Ciccozzi M, Prosperi MCF, et al. Emergence of recombinant Mayaro virus strains from the Amazon basin. Sci Rep [Internet]. 2017;7(1):8718. Available from: http://europepmc.org/articles/PMC5562835
Cárdenas-Marrufo MF, Pech-Sosa N, Arias-León JJ. Fiebre Mayaro: Enfermedad emergente al acecho. Cienc Y HUMANISMO EN LA SALUD. 2017;3(3):32–40.
Terzian ACB, Auguste AJ, Vedovello D, Ferreira MU, da Silva- Nunes M, Sperança MA, et al. Isolation and Characterization of Mayaro Virus from a Human in Acre, Brazil. Am J Trop Med Hyg. 2015;92(2).